McKesson outlines fiscal 2027 adjusted EPS of $44.20 to $45.00 while planning $5B in share repurchases (NYSE:MCK)

McKesson (MCK) Q1 FY2027 earnings call: raised EPS guide to $44.20–$45.00, strong revenue, GLP-1 trends, Wellverse spinoff—read now.

McKesson outlines fiscal 2027 adjusted EPS of $44.20 to $45.00 while planning $5B in share repurchases (NYSE:MCK) | Seeking Alpha

Earnings Call Insights: McKesson (MCK) Q1 fiscal 2027

Management View

CEO & Chairman Brian Tyler said the quarter showed “broad-based momentum across the enterprise” as “Revenues increased 8% to $105 billion and adjusted earnings per diluted share increased 20% to $9.93,” and added that the performance “gives us the confidence to

Seeking Alpha's Disclaimer:

This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please

report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search field

Entering text into the input field will update the search result below

Quick Insights

Why did McKesson raise its fiscal 2027 EPS outlook?

McKesson raised its fiscal 2027 EPS outlook due to strong Q1 performance, broad-based momentum, and confidence in ongoing operational execution.

What are the main risks facing McKesson currently?

Main risks include lower branded pharmaceutical pricing, branded to generic conversions, uncertain policy impacts (e.g. 340B), and separation-related financing effects.

How is the Medical-Surgical Solutions separation impacting McKesson?

The separation led to the Apollo minority investment, new stand-alone debt financing, establishing the business as Wellverse starting January 2027, and related accounting adjustments and interest expenses.

Recommended For You

More

Trending News

See More

»